Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration

Br J Haematol. 2020 May;189(3):e108-e111. doi: 10.1111/bjh.16531. Epub 2020 Feb 20.

¹ Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Women and Child Health, University of Padova, Padova, Italy.
² Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy.
³ Department of Pediatric Hemato-Oncology, Ospedale Bambino Gesù, Rome, Italy.
⁴ Department of Paediatrics, University of Milano-Bicocca, Fondazione MBBM, Azienda Ospedaliera S. Gerardo, Monza, Italy.
⁵ Department of Paediatric Haemato-Oncology, IRCCS Istituto 'Giannina Gaslini', Genova, Italy.
⁶ Department of Biomedical Science and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
⁷ Paediatric Haematology, Department of Paediatrics, University Hospital Città della Salute e della Scienza di Torino, Torino, Italy.
⁸ Division of Paediatric Oncology-Haematology, Policlinico Hospital, Modena, Italy.
⁹ Department of Paediatric Haemato-Oncology, Santobono-Pausilipon Children's Hospital, Napoli, Italy.
¹⁰ Department of Pathology, San Bortolo Hospital, Vicenza, Italy.
¹¹ Gene Therapy Program, Dana Farber/Boston Children's Cancer and Blood Disorders Centers, Boston, MA, USA.

No abstract available

Keywords: AIEOP LNH-97; B-cell acute leukaemia; Burkitt; anti-CD20; minimal residual disease; paediatric.

Publication types